An Open-Label, Dose Escalation Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-1045 (CN201) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Latest Information Update: 05 Jun 2025
At a glance
- Drugs CN 201 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Sponsors Curon Biopharmaceutical
Most Recent Events
- 13 May 2025 Planned End Date changed from 1 Dec 2025 to 30 Sep 2027.
- 13 May 2025 Planned primary completion date changed from 1 Jun 2025 to 31 Mar 2027.
- 04 Jun 2024 Results ( As of December 29, 2023, n=58) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.